---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-011512"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:40:16.551449+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q1 FY2023 net loss $1.7M; FDA cleared Evo sEEG electrode

## Summary
- Product revenue $115K (vs $34K YoY); collaboration revenue $1.46M from Zimmer agreement.
- Net loss $1.7M (improved from $2.8M); cash $7.6M, no debt as of Dec 31, 2022.
- FDA 510(k) clearance for Evo sEEG electrode; first commercial order shipped to Zimmer Biomet.
- Targeting OneRF ablation system 510(k) submission in Q2 calendar 2023; spinal cord stimulation electrodes in pre-clinical.
- R&D expense $1.6M (up from $1.1M); SG&A flat at $1.7M; total op ex $3.2M.

## SEC filing metadata
- accession: 0001213900-23-011512
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390023011512/0001213900-23-011512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390023011512/ea173234-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-011512
- JSON: https://secwatch.observer/filing/0001213900-23-011512.json
- Plain text: https://secwatch.observer/filing/0001213900-23-011512.txt

## Key facts
- Earnings Releases
  NEUROONE MEDICAL TECHNOLOGIES Corp reported financial results for the fiscal first quarter 2023 ended December 31, 2022.
  - Period: the fiscal first quarter 2023 ended December 31, 2022
  - Result: reported results
  source text: On February 14, 2023, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390023011512/0001213900-23-011512-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.